Minimal residual disease (MRD) assessment is incorporated in an increasing number of
multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a …

Despite considerable advances in treatment approaches in the past two decades, multiple
myeloma remains an incurable disease. Treatments for myeloma continue to evolve with …

In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell
transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for …

Immunotherapy is changing the paradigm of multiple myeloma (MM) management and
daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for …

Survival in multiple myeloma has improved greatly during the past 2 decades, but this
change has primarily benefited patients who have standard-risk disease. Patients with high …

The changing landscape of treatment options for multiple myeloma has led to a higher
proportion of patients achieving deep, long-lasting responses to therapy. With the …

Multiple Myeloma (MM), the second most common hematologic malignancy, has been the
target of many therapeutic advances over the past two decades. The introduction of novel …

Multiple Myeloma, the second most prevalent hematologic malignancy, yet lacks an
established curative therapy. However, overall response rate to modern four-drug regimens …

Recent advances in multiple myeloma include numerous approvals of novel therapies with
unprecedented efficacy, a rapid and sustained tempo of new drug development, and further …

Minimal residual disease (MRD) detection represents a sensitive tool to appropriately
measure the response obtained with therapies for multiple myeloma (MM). The achievement …